Eupraxia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EPRX.TO | INVA | EIKN | LXRX | PHAT | ZVRA | |
|---|---|---|---|---|---|---|
| Market cap | 617.79M | 1.50B | 401.90M | 676.33M | 559.83M | 590.27M |
| P/E (TTM) | — | 4.9 | — | — | — | 10.8 |
| Forward P/E | -6.4 | 9.4 | -1.2 | -8.0 | 6.4 | 9.2 |
| Price/book | 4.2 | 1.2 | 0.9 | 3.9 | -1.6 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +18.60% | +20.74% | −49.73% | +16.20% | −50.61% | −10.85% |
| Today | −2.91% | −0.38% | −1.59% | −7.88% | −7.73% | −3.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EPRX.TO news ›Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Investing News Network Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis - Eupraxia reached its target enrollment of 120 patients in the Phase…
Eupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment Target
marketscreener.com Biotechnology & Medical Research Eupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment Target Published on 10/15/2026 at 08:57 am EDT
Eupraxia Pharmaceuticals Showcases EP-104GI EoE Data at Major Gastroenterology Meetings
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an announcement. The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see…
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
The randomized, placebo-controlled portion of RESOLVE is recruiting patients at both doses under study. Eupraxia Pharmaceuticals (EPRX) will present three abstracts on its ongoing RESOLVE trial of EP-104GI at upcoming gastroenterology…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
investingnews.com1
-
tipranks.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.